JP2005508322A5 - - Google Patents

Download PDF

Info

Publication number
JP2005508322A5
JP2005508322A5 JP2003530213A JP2003530213A JP2005508322A5 JP 2005508322 A5 JP2005508322 A5 JP 2005508322A5 JP 2003530213 A JP2003530213 A JP 2003530213A JP 2003530213 A JP2003530213 A JP 2003530213A JP 2005508322 A5 JP2005508322 A5 JP 2005508322A5
Authority
JP
Japan
Prior art keywords
suramin
agent
interleukin
kit
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003530213A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508322A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/030210 external-priority patent/WO2003026574A2/en
Publication of JP2005508322A publication Critical patent/JP2005508322A/ja
Publication of JP2005508322A5 publication Critical patent/JP2005508322A5/ja
Pending legal-status Critical Current

Links

JP2003530213A 2001-09-24 2002-09-24 併用療法に用いられるスラミンの化学増感用量を決定するための方法及び成分 Pending JP2005508322A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32470401P 2001-09-24 2001-09-24
PCT/US2002/030210 WO2003026574A2 (en) 2001-09-24 2002-09-24 Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy

Publications (2)

Publication Number Publication Date
JP2005508322A JP2005508322A (ja) 2005-03-31
JP2005508322A5 true JP2005508322A5 (OSRAM) 2006-01-12

Family

ID=23264730

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003530213A Pending JP2005508322A (ja) 2001-09-24 2002-09-24 併用療法に用いられるスラミンの化学増感用量を決定するための方法及び成分

Country Status (9)

Country Link
US (2) US20040180955A1 (OSRAM)
EP (1) EP1429713A4 (OSRAM)
JP (1) JP2005508322A (OSRAM)
KR (1) KR20040062546A (OSRAM)
CN (1) CN100441176C (OSRAM)
AU (1) AU2002330088B2 (OSRAM)
CA (1) CA2461227C (OSRAM)
IL (1) IL161036A0 (OSRAM)
WO (1) WO2003026574A2 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2007065016A2 (en) * 2005-12-02 2007-06-07 Au Jessie L S Methods and compositions to improve activity and reduce toxicity of stents
JP2010535232A (ja) * 2007-07-30 2010-11-18 アルディア バイオサイエンス,インク. Mekの阻害剤としての多形体を含む、n−(アリールアミノ)スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法
EP2750768B1 (en) 2011-08-30 2018-10-03 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
CN104398517A (zh) * 2014-11-28 2015-03-11 四川大学 乙胺嘧啶的新用途及治疗肿瘤的药物组合物
KR20180024010A (ko) 2015-07-02 2018-03-07 오쓰까 세이야꾸 가부시키가이샤 동결건조된 약제학적 조성물
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑
EP3661522A2 (en) 2017-08-03 2020-06-10 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597830A (en) * 1994-12-20 1997-01-28 Warner-Lambert Company Combination chemotherapy
ATE302599T1 (de) * 1996-05-24 2005-09-15 Angiotech Pharm Inc Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
JP2001500899A (ja) * 1997-03-11 2001-01-23 レ ラボラトワール エテルナ インコーポレイティド 高い効能及び少ない副作用を供与する軟骨エキスと抗新形成剤との組合せを含んで成る抗腫瘍療法
US6506783B1 (en) * 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6599912B1 (en) * 1999-06-03 2003-07-29 Jessie L. -S. Au Methods and compositions for modulating cell proliferation and cell death
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same

Similar Documents

Publication Publication Date Title
JP2005508322A5 (OSRAM)
JP5846822B2 (ja) 栄養又は治療組成物
JP2017519753A5 (OSRAM)
CA2461227A1 (en) Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
CA2503730A1 (en) Cytarabine monophosphate prodrugs
ES2738983T3 (es) Composición y procedimiento para la administración segura y eficaz de halopiruvato para el tratamiento del cáncer
ES2200316T3 (es) Composiciones para tratar tumores que contienen extractos de cartilago de tiburon y agentes antineoplasticos.
RU2016133168A (ru) Изоксазолиновые композиции и их применение в качестве противопаразитарных средств
HRP20110245T1 (hr) Derivati pirazolopirimidina kao inhibitori o ciklinu ovisne kinaze
RU2006146619A (ru) Лечение гемцитабином и ингибитором рецептора эпидермального фактора роста(egfr)
JP2006507308A5 (OSRAM)
JP2010533206A5 (OSRAM)
AU2010208062B2 (en) Compositions and methods for the treatment of cancer
RU2003108822A (ru) Улучшенная противоопухолевая композиция на основе паклитаксела
RU2007134571A (ru) Комбинация и способы введения терапевтических средств и комбинированной терапии
HRP20110578T1 (hr) Kombinacije za liječenje bolesti koje uključuju proliferaciju stanica
CN102688492A (zh) 包含四环素类的抗炎组合物及其用途
JP2004501870A5 (OSRAM)
RU2010145048A (ru) On01910.na, усиливающий активность химиотерапевтического агента в резистентных к лекарственным средствам опухолях
JP2009511590A5 (OSRAM)
JPWO2007108272A1 (ja) 癌治療用キットおよび癌治療用医薬組成物
JP2025111546A (ja) Fms様チロシンキナーゼ3リガンド(flt3l)ベースキメラタンパク質
CA2648945A1 (en) Chemoprotective methods and compositions
HK1052874A1 (en) Compositions containing a naphthalmide and an antiproliferative agent
US20020037328A1 (en) Hexitol compositions and uses thereof